Answers are grounded in this paper and cite their sources.
Dr Barbara Kohn's group at the Clinic for Small Animals of the Freie University Berlin, Germany, recently reported on crossmatch results in (pre-) transfused dogs in JVIM.1 These authors used a tube crossmatch method without canine antiglobulins to assess the potential appearance of alloantibodies posttransfusion. They reported that a subset of 21 transfused tested dogs was exhibiting “very weak” microscopic agglutination reactions before and within hours to days after transfusion. These responses were nonrising over time and often disappeared rapidly after blood transfusion. Based on these data, they claim that alloantibodies developed within hours to days posttransfusion and recommend that all dogs requiring transfusion should be crossmatched at day 1, instead of the current practice of crossmatching 4 days posttransfusion.1 In conclusion, I believe the authors' data does not provide specific evidence of alloantibody development before and shortly after transfusion nor does it support the need for recommending crossmatching before 4 days after a first transfusion in dogs. Rather than ignoring or refuting current immunology standard principles, Kohn's study likely exemplifies the unspecificity of a nonantiglobulin enhanced crossmatch and the questionable value of weakly positive crossmatch results. As such, their recommendations may unnecessarily delay and even prevent timely transfusions. Finally, the continued use of xenotransfusions in cats, which have been known for more than a century to elicit immediately strong incompatibility reactions in vivo, because of the presence of preexisting naturally occurring antierythrocytic xenoantibodies.9 should pause anyone to consider “very weak” microscopic agglutination as evidence of any acute alloimmune hemolytic transfusion reaction. Such reactions are completely different from alloantibody responses induced by transfusion of canine blood with an incompatible blood type and clinicians should not automatically conclude that unspecific minor agglutination reactions are clinically relevant, as this would deter transfusion of animals in need of life-saving transfusions. The author has been a scientific advisor to various companies involved in blood compatibility testing including Alvedia, DMS Laboratories and some lectures on transfusion medicine at conferences have been supported by companies.
No takes yet. Share an insight, caveat, or question.
Urs Giger (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: